Pyxis Oncology, Inc. Profile Avatar - Palmy Investing

Pyxis Oncology, Inc.

Pyxis Oncology, Inc., a preclinical stage biopharmaceutical company, engages in the development of therapies to treat cancers. Its immune-oncology product candidates include PYX-106, an investigational fully human immunoglobulin G1 isotype siglec-15 targ…

Biotechnology
US, Cambridge [HQ]
Strategy & Leadership

Officers & BofD Beta

  • Form 3/4/5
  • Proxy DEF-14A

Total Compensation

- No data, only available if we have DEF 14A compensations in place -
Officers
Name & Position Research Last Appearance
- No data available -
Board of Directors (BofD)
Name & Position Research Last Appearance
- No data available -
End of PYXS's Analysis
CIK: 1782223 CUSIP: 747324101 ISIN: US7473241013 LEI: - UEI: -
Secondary Listings
PYXS has no secondary listings inside our databases.